Physician profile
John G Wallace
NPI 1831486596
$7,386.69
in general payments reported to CMS, 2019-2025
31 companies · $796 in 2025
The $796 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $714 · 2021: $1,067 · 2022: $1,198 · 2023: $1,384 · 2024: $1,412 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,591.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,477.76 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,141.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,030.36 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $961.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $562.77 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.61 | 2019-2024 | Ofev |
| Pfizer INC. | $344.98 | 2019-2025 | |
| Lilly USA, LLC | $265.11 | 2019-2024 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.31 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $133.49 | 2019-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $107.94 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $101.88 | 2020-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Allergan, INC. | $73.66 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.84 | 2021-2024 | |
| Abbott Laboratories | $63.18 | 2021-2024 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $59.03 | 2019-2024 | Eliquis |
| Medtronic, INC. | $56.50 | 2023-2024 | Intellis Adaptivestim, Interstim |
| Takeda Pharmaceuticals U.S.A., INC. | $54.69 | 2021 | |
| Sanofi-Aventis U.S. LLC | $50.51 | 2019 | |
| Astellas Pharma US INC | $41.21 | 2019-2023 | Veozah |
| Mylan Specialty L.P. | $34.60 | 2019-2023 | Yupelri |
| Sanofi Pasteur INC. | $29.27 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $24.45 | 2021 | |
| Csl Behring | $23.11 | 2025 | Andembry |
| Dexcom, INC. | $22.83 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.68 | 2021 | |
| Sumitomo Pharma America, INC. | $17.01 | 2023 | Gemtesa |
| Inari Medical, INC. | $14.21 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $14.17 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.73 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $13.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.